215 related articles for article (PubMed ID: 25483727)
1. Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Isoyama S; Kajiwara G; Tamaki N; Okamura M; Yoshimi H; Nakamura N; Kawamura K; Nishimura Y; Namatame N; Yamori T; Dan S
Cancer Sci; 2015 Feb; 106(2):171-8. PubMed ID: 25483727
[TBL] [Abstract][Full Text] [Related]
2. Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance.
Isoyama S; Dan S; Nishimura Y; Nakamura N; Kajiwara G; Seki M; Irimura T; Yamori T
Cancer Sci; 2012 Nov; 103(11):1955-60. PubMed ID: 22925034
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
Yaguchi S; Fukui Y; Koshimizu I; Yoshimi H; Matsuno T; Gouda H; Hirono S; Yamazaki K; Yamori T
J Natl Cancer Inst; 2006 Apr; 98(8):545-56. PubMed ID: 16622124
[TBL] [Abstract][Full Text] [Related]
4. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
[TBL] [Abstract][Full Text] [Related]
5. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Dan S; Okamura M; Mukai Y; Yoshimi H; Inoue Y; Hanyu A; Sakaue-Sawano A; Imamura T; Miyawaki A; Yamori T
Eur J Cancer; 2012 Apr; 48(6):936-43. PubMed ID: 22088482
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Kong D; Okamura M; Yoshimi H; Yamori T
Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Dan S; Yoshimi H; Okamura M; Mukai Y; Yamori T
Biochem Biophys Res Commun; 2009 Jan; 379(1):104-9. PubMed ID: 19094964
[TBL] [Abstract][Full Text] [Related]
8. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
9. Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.
Li XX; Huang LY; Peng JJ; Liang L; Shi DB; Zheng HT; Cai SJ
Int J Oncol; 2014 Aug; 45(2):611-8. PubMed ID: 24818842
[TBL] [Abstract][Full Text] [Related]
10. Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Isoyama S; Yoshimi H; Dan S; Okamura M; Seki M; Irimura T; Yamori T
Biol Pharm Bull; 2012; 35(9):1607-13. PubMed ID: 22975517
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.
Tian X; Hao K; Qin C; Xie K; Xie X; Yang Y
Dig Dis Sci; 2013 Sep; 58(9):2705-12. PubMed ID: 23589145
[TBL] [Abstract][Full Text] [Related]
12. IGF-I stimulates ERβ and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis.
Zhou Y; Zeng C; Li X; Wu PL; Yin L; Yu XL; Zhou YF; Xue Q
J Mol Med (Berl); 2016 Aug; 94(8):887-97. PubMed ID: 26899323
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
14. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
16. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A; Jebaraj BMC; Tausch E; Bloehdorn J; Ghia P; Yahiaoui A; Dolnik A; Blätte TJ; Bullinger L; Dheenadayalan RP; Li L; Schneider C; Chen SS; Chiorazzi N; Dietrich S; Seiffert M; Tannheimer S; Döhner H; Mertens D; Stilgenbauer S
Blood; 2019 Aug; 134(6):534-547. PubMed ID: 31010847
[TBL] [Abstract][Full Text] [Related]
17. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Kong D; Dan S; Yamazaki K; Yamori T
Eur J Cancer; 2010 Apr; 46(6):1111-21. PubMed ID: 20129775
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Zhao YW; Jin L; Li ZM; Zhao CJ; Wei YQ; Yang HS
Cancer Sci; 2011 Aug; 102(8):1469-75. PubMed ID: 21561530
[TBL] [Abstract][Full Text] [Related]
19. Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
de Lint K; Poell JB; Soueidan H; Jastrzebski K; Vidal Rodriguez J; Lieftink C; Wessels LF; Beijersbergen RL
Mol Cancer Ther; 2016 Jul; 15(7):1545-56. PubMed ID: 27196766
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
